Hisamitsu Pharmaceutical Co., Inc.
HTSUF · OTC
2/28/2025 | 2/28/2024 | 2/28/2023 | 2/28/2022 | |
|---|---|---|---|---|
| Revenue | $156,006 | $141,706 | $128,330 | $120,193 |
| % Growth | 10.1% | 10.4% | 6.8% | – |
| Cost of Goods Sold | $64,810 | $62,735 | $55,630 | $50,126 |
| Gross Profit | $91,196 | $78,971 | $72,700 | $70,067 |
| % Margin | 58.5% | 55.7% | 56.7% | 58.3% |
| R&D Expenses | $0 | $8,614 | $9,785 | $10,613 |
| G&A Expenses | $26,526 | $25,290 | $23,218 | $20,582 |
| SG&A Expenses | $72,300 | $57,189 | $51,314 | $50,117 |
| Sales & Mktg Exp. | $34,871 | $31,899 | $28,096 | $29,535 |
| Other Operating Expenses | $1 | $1 | $0 | $0 |
| Operating Expenses | $72,301 | $65,804 | $61,099 | $60,730 |
| Operating Income | $18,895 | $13,167 | $11,599 | $9,337 |
| % Margin | 12.1% | 9.3% | 9% | 7.8% |
| Other Income/Exp. Net | $9,792 | $6,019 | $4,513 | $3,618 |
| Pre-Tax Income | $28,687 | $19,186 | $16,113 | $12,956 |
| Tax Expense | $6,385 | $4,754 | $3,987 | $3,093 |
| Net Income | $21,758 | $13,969 | $11,742 | $9,658 |
| % Margin | 13.9% | 9.9% | 9.1% | 8% |
| EPS | 295.57 | 181.61 | 148 | 118.92 |
| % Growth | 62.7% | 22.7% | 24.5% | – |
| EPS Diluted | 295.15 | 181.42 | 147.87 | 118.84 |
| Weighted Avg Shares Out | 74 | 77 | 79 | 81 |
| Weighted Avg Shares Out Dil | 74 | 77 | 79 | 81 |
| Supplemental Information | – | – | – | – |
| Interest Income | $2,748 | $2,564 | $894 | $153 |
| Interest Expense | $23 | $18 | $15 | $20 |
| Depreciation & Amortization | $6,335 | $5,172 | $4,952 | $4,321 |
| EBITDA | $35,045 | $24,376 | $16,553 | $17,297 |
| % Margin | 22.5% | 17.2% | 12.9% | 14.4% |